NcXHF

SUSAN F. SLOVIN
placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983-
992.
5. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate
cancer without previous chemotherapy. N Engl J Med. 2013;368:138-148.
6. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel
or mitoxantrone for metastatic castration-resistant prostate cancer progressing
after docetaxel treatment: a randomised open-label trial. Lancet
Oncol. 2010;376:1147-1154.
7. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and
survival in metastatic prostate cancer. N Engl J Med. 2013;369:213-223.
8. Schellhammer PF, Chodak G, Whitmore JB, et al. Lower baseline
prostate-specifıc antigen is associated with a greater overall survival
benefıt from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma
Treatment (IMPACT) trial. Urology. 2013;81:1297-1302.
9. Drake CG, Fan L-Q, GuhaThakurta D, et al. Antigen spread and survival
with sipuleucel-T in patients with advanced prostate cancer. J Clin Oncol.
2014;32:4s (suppl; abstr 88).
10. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis
of a phase II randomized controlled trial of a Poxviral-based PSAtargeted
immunotherapy in metastatic castration-resistant prostate
cancer. J Clin Onc. 2010;28:1099-1105.
11. Sheikh NA, Jones LA. CD54 is a surrogate marker of antigen presenting
cell activation. Cancer Immunol Immunother. 2008;57:1381-1390.
12. Sheikh NA, Petrylak D, Kantoff PW, et al. Sipuleucel-T immune parameters
correlate with survival: an analysis of the randomized phase 3 clinical
trials in men with castration-resistant prostate cancer. Cancer
Immunol Immunother. 2013;62:137-147.
13. Loken MR, Brosnan JM, Bach BA, et al. Establishing optimal lymphocyte
gates for immunophenotyping by flow cytometry. Cytometry. 1990;
11:453-459.
14. Gaglia JL, Greenfıeld EA, Mattoo A, et al. Intercelluar adhesion molecule
1 is critical for activation of CD28-defıcient T cells. J Immunol.
2000;165:6091-6098.
15. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2
randomized, double-blind, placebo-controlled, phase 3 trials of active
cellular immunotherapy with sipuleucel-T in advanced prostate cancer.
Cancer. 2009;115:3670-3679.
16. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase
III trial of immunologic therapy with sipuleucel-T (APC8015) in patients
with metastatic, asymptomatic hormone refractory prostate cancer.
J Clin Oncol. 2006;24:3089-3094.
17. Fong L, Carroll P, Weinberg V, et al. Activated lymphocyte recruitment
into the tumor microenvironment following preoperative sipuleucel-T
for localized prostate cancer. J Natl Cancer Inst. Epub 2014 Oct 1.
18. Pagés F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T
cells predict outcome in patients with early-stage colorectal cancer.
J Clin Oncol. 2009;27:5944-5951.
19. Pagés F, Berger A, Camus M, et al. Effector memory T cells, early metastasis,
and survival in colorectal cancer. N Engl J Med. 2005;353:2654-
2666.
20. McNeel DG, Gardner TA, Higano CS, et al. A transient increase in eosinophils
is associated with prolonged survival in men with metastatic
castration-resistant prostate cancer who receive sipuleucel-T. Cancer
Immunol Res. 2014;2:988-999.
21. Antonarakis ES, et al. Randomized phase II trial evaluating the optimal
sequencing of sipileicel-T and androgen-deprivatino therapy (ADT) in
patients (PTS) with biochemically recurrent prostate cancer (BRPC).
J Clin Oncol. 2013;31:6s (suppl; abstr 34).
22. Antonarakis ES, Kibel AS, Adams GW, et al. A randomized phase 2
study evaluating the optimal sequencing of sipuleucel-T and androgen
deprivation therapy in biochemically-recurrent prostate cancer: immune
results with a focus on humoral responses. Paper presented at:
29th Annual EAU Congress; April 2014; Stockholm, Sweden.
23. Drake C, Kibel AS, Adams GW, et al. A randomized phase 2 study evaluating
optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation
therapy (ADT) in biochemically recurrent prostate cancer
(BRPC): variables that correlate with immune response. Paper presented
at: ESMO 2014; September 2014; Madrid, Spain.
24. Madan RA, Mohebtash M, Arlen PM, et al. Overall survival (OS) analysis
of a phase l trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab
(Ipi) in the treatment of metastatic castration-resistant
prostate cancer (mCRPC). J Clin Onc. 2010;28:20s 20 (suppl; abstr
2550).
25. Small EJ, Lance R, Gardner T, et al. A randomized phase II, open-label
study of sipuleucel-T with concurrent or sequential abiraterone acetate
(AA) in metastatic castrate-resistant prostate cancer (mCRPC). J Clin
Oncol. 2013;31:6s (suppl; abstr 114).
26. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab
in patients with metastatic melanoma. N Engl J Med. 2010;363:
711-723.
27. Slovin SF, Higano CS, Hamid O, et al. Ipilimumab alone or in combination
with radiotherapy in metastatic castration-resistant prostate
cancer: results from an open-label, multicenter phase I/II study. Ann
Oncol. 2013;24:1813-1821.
28. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after
radiotherapy in patients with metastatic castration-resistant prostate
cancer that had progressed after docetaxel chemotherapy (CA184-043):
a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol.
2014;15:700-712.
29. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:
2443-2454.
30. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with
lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2012;369:134-
144.
31. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response
to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189-
2199.
32. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis
of a phase II randomized controlled trial of a Poxviral-based PSAtargeted
immunotherapy in metastatic castration-resistant prostate
cancer. J Clin Oncol. 2010;28:1099-1105.
33. Gulley JL, Arlen PM, Madan RA, et al. Immunologic and prognostic
factors associated with overall survival employing a poxviral-based PSA
vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol
Immunother. 2010;59:663-674.
34. Madan RA, Gulley JL, Fojo T, et al. Therapeutic cancer vaccines in prostate
cancer: the paradox of improved survival without changes in time to
progression. Oncologist. 2010;15:969-975.
35. Arlen PM, Gulley, JL, Madan RA, et al. Preclinical and clinical studies of
recombinant poxvirus vaccines for carcinoma therapy. Crit Rev Immunol.
2007;27:451-462.
36. Harrington LE, Most Rv Rv, Whitton JL, et al. Recombinant vaccinia
virus-induced T-cell immunity: quantitation of the response to the virus
vector and the foreign epitope. J Virol. 2002;76:3329-3337.
37. Madan RA, Arlen PM, Mohebtash M, et al. Prostvac-VF: a vector-based
vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs.
2009;18:1001-1011.
38. Schweizer MT, Drake CG. Immunotherapy for prostate cancer: recent
developments and future challenges. Cancer Metastasis Rev. 2014;33:
641-655.
39. Gulley JL, Madan RA, Stein WD, et al. Effect of PSA-tricom, a pox-viral
vaccine in prostate cancer (PCa), on tumor growth rates within 80 days
e282
2015 ASCO EDUCATIONAL BOOK | asco.org/edbook